Anders Helander

List of Publications by Year in Descending Order

164 papers	6,130 citations	47 h-index	70 g-index
178 ext. papers	6,811 ext. citations	3.4 avg, IF	6.08 L-index

#	Paper	IF	Citations
164	Minor effect of patient education for alcohol cessation intervention on outcomes after acute fracture surgery: a randomized trial of 70 patients.. *Monthly Notices of the Royal Astronomical Society: Letters*, **2022**, 93, 424-431	4.3	
163	Measurement of the alcohol biomarker phosphatidylethanol (PEth) in dried blood spots and venous blood-importance of inhibition of post-sampling formation from ethanol. *Analytical and Bioanalytical Chemistry*, **2021**, 413, 5601-5606	4.4	5
162	Performance of PEth Compared With Other Alcohol Biomarkers in Subjects Presenting For Occupational and Pre-Employment Medical Examination. *Alcohol and Alcoholism*, **2020**, 55, 401-408	3.5	8
161	Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project. *PLoS ONE*, **2020**, 15, e0232038	3.7	9
160	Sensitive determination of ethyl glucuronide in serum and whole blood: detection time after alcohol exposure compared with urine. *Journal of Laboratory Medicine*, **2020**, 44, 211-219	0.9	3
159	-Hydroxybutyrate does not mediate glucose inhibition of glucagon secretion. *Journal of Biological Chemistry*, **2020**, 295, 5419-5426	5.4	1
158	Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project **2020**, 15, e0232038		
157	Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project **2020**, 15, e0232038		
156	Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project **2020**, 15, e0232038		
155	Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project **2020**, 15, e0232038		
154	Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project **2020**, 15, e0232038		
153	Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project **2020**, 15, e0232038		
152	Dose-Response Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth)-A Study of Outpatients in Treatment for Reduced Drinking. *Alcohol and Alcoholism*, **2019**, 54, 567-573	3.5	15
151	Elimination Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth) in Blood during Alcohol Detoxification. *Alcohol and Alcoholism*, **2019**, 54, 251-257	3.5	22
150	Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease. *Veterinary Journal*, **2019**, 250, 36-43	2.5	2
149	Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project. *Clinical Toxicology*, **2019**, 57, 203-212	2.9	27
148	An analytically confirmed non-fatal intoxication by carfentanil in Sweden. *Clinical Toxicology*, **2019**, 57, 372-374	2.9	4

147	The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union. *Clinical Chemistry*, **2019**, 65, 242-253	5.5	68
146	Chemical synthesis, characterisation and in vitro and in vivo metabolism of the synthetic opioid MT-45 and its newly identified fluorinated analogue 2F-MT-45 with metabolite confirmation in urine samples from known drug users. *Forensic Toxicology*, **2018**, 36, 359-374	2.6	22
145	Study of measurement of the alcohol biomarker phosphatidylethanol (PEth) in dried blood spot (DBS) samples and application of a volumetric DBS device. *Clinica Chimica Acta*, **2018**, 479, 38-42	6.2	26
144	Detectability of fentanyl and designer fentanyls in urine by 3 commercial fentanyl immunoassays. *Drug Testing and Analysis*, **2018**, 10, 1297	3.5	24
143	Investigation of drug products received for analysis in the Swedish STRIDA project on new psychoactive substances. *Drug Testing and Analysis*, **2018**, 10, 340-349	3.5	17
142	Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry. *Drug Testing and Analysis*, **2018**, 10, 496-506	3.5	21
141	Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. *Clinical Toxicology*, **2018**, 56, 256-263	2.9	32
140	Acute Intoxications Involving α-Pyrrolidinobutiophenone (α-PBP): Results from the Swedish STRIDA Project. *Journal of Medical Toxicology*, **2018**, 14, 265-271	2.6	12
139	Urine analysis of 28 designer benzodiazepines by liquid chromatography–high-resolution mass spectrometry. *Clinical Mass Spectrometry*, **2018**, 10, 25-32	1.9	8
138	Epidemiology of NPS Based Confirmed Overdose Cases: The STRIDA Project. *Handbook of Experimental Pharmacology*, **2018**, 252, 461-473	3.2	8
137	Identification and quantitation of phosphatidylethanols in oral fluid by liquid chromatography-tandem mass spectrometry. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1332-1339	3.9	4
136	Use of LC-HRMS in full scan-XIC mode for multi-analyte urine drug testing - a step towards a "black-box" solution?. *Journal of Mass Spectrometry*, **2017**, 52, 497-506	2.2	17
135	"Adulterant or contaminant in MT-45, or coingestion?" "Reply from the authors. *British Journal of Dermatology*, **2017**, 177, 582-583	4	
134	Reprint of Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT). *Clinica Chimica Acta*, **2017**, 467, 15-20	6.2	12
133	Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project. *Clinical Toxicology*, **2017**, 55, 589-599	2.9	77
132	Higher alcohol consumption in early pregnancy or low-to-moderate drinking during pregnancy may affect children's behaviour and development at one year and six months. *Acta Paediatrica, International Journal of Paediatrics*, **2017**, 106, 446-453	3.1	5
131	IFCC approved HPLC reference measurement procedure for the alcohol consumption biomarker carbohydrate-deficient transferrin (CDT): Its validation and use. *Clinica Chimica Acta*, **2017**, 465, 91-100	6.2	24
130	Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45. *British Journal of Dermatology*, **2017**, 176, 1021-1027	4	71

129	Rs nitrogen mustard contamination responsible for the reported MT-45 toxicity?RReply from the authors. *British Journal of Dermatology*, **2017**, 177, 595	4	
128	New Psychoactive Substances (NPS) - the Hydra monster of recreational drugs. *Clinical Toxicology*, **2017**, 55, 1-3	2.9	34
127	Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. *Drug Testing and Analysis*, **2017**, 9, 640-645	3.5	55
126	Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project. *Journal of Medical Toxicology*, **2017**, 13, 52-60	2.6	54
125	Synthetic Cannabinoid Receptor Agonists (Spice) as New Recreational Psychoactive Substances **2017**, 839-847		1
124	Feasibility and Acceptability of an Alcohol Addiction Therapy Integrated in a Transplant Center for Patients Awaiting Liver Transplantation. *Alcohol and Alcoholism*, **2016**, 51, 40-6	3.5	9
123	Intoxications involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfentanyl: results from the Swedish STRIDA project. *Clinical Toxicology*, **2016**, 54, 324-32	2.9	115
122	Integration of Clinical Examination, Self-Report, and Hair Ethyl Glucuronide Analysis for Evaluation of Patients With Alcoholic Liver Disease Prior to Liver Transplantation. *Progress in Transplantation*, **2016**, 26, 40-6	1.1	5
121	Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT). *Clinica Chimica Acta*, **2016**, 459, 19-24	6.2	31
120	Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. *Analytical and Bioanalytical Chemistry*, **2016**, 408, 3571-91	4.4	50
119	Toxicity evaluation of □pyrrolidinovalerophenone (□PVP): results from intoxication cases within the STRIDA project. *Clinical Toxicology*, **2016**, 54, 568-75	2.9	41
118	Development and application of a multi-component LC-MS/MS method for determination of designer benzodiazepines in urine. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1035, 104-110	3.2	42
117	Adverse events related to the new psychoactive substance 3-fluorophenmetrazine - results from the Swedish STRIDA project. *Clinical Toxicology*, **2016**, 54, 819-825	2.9	19
116	Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. *Clinical Toxicology*, **2015**, 53, 609-17	2.9	120
115	Alcohol intake measured by phosphatidylethanol in blood and the lifetime drinking history interview are correlated with the extent of psoriasis. *Dermatology*, **2015**, 230, 375-80	4.4	15
114	Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. *Clinical Toxicology*, **2015**, 53, 446-53	2.9	58
113	Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. *Clinical Toxicology*, **2015**, 53, 856-64	2.9	53
112	Intoxications involving MDPV in Sweden during 2010-2014: Results from the STRIDA project. *Clinical Toxicology*, **2015**, 53, 865-73	2.9	41

111	Comparison of self-reported alcohol use with the alcohol biomarker phosphatidylethanol among young people in northern Tanzania. *Drug and Alcohol Dependence*, **2015**, 156, 289-296	4.9	27
110	Validation of the MINI (DSM IV) Tool for the Assessment of Alcohol Dependence among Young People in Northern Tanzania Using the Alcohol Biomarker Phosphatidylethanol (PEth). *International Journal of Environmental Research and Public Health*, **2015**, 12, 14021-33	4.6	6
109	Phosphatidylethanols in breath: a possible noninvasive screening test for heavy alcohol consumption. *Clinical Chemistry*, **2015**, 61, 991-3	5.5	12
108	Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. *Clinical Toxicology*, **2015**, 53, 46-53	2.9	60
107	Detectability of new psychoactive substances, ‘legal highs’, in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse. *Drug Testing and Analysis*, **2014**, 6, 492-9	3.5	31
106	Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. *Forensic Science International*, **2014**, 243, 23-9	2.6	95
105	Comparison of ethyl glucuronide and carbohydrate-deficient transferrin in different body fluids for post-mortem identification of alcohol use. *Alcohol and Alcoholism*, **2014**, 49, 55-9	3.5	21
104	MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. *Clinical Toxicology*, **2014**, 52, 901-4	2.9	132
103	Intoxications of the new psychoactive substance 5-(2-aminopropyl)indole (5-IT): a case series from the Swedish STRIDA project. *Clinical Toxicology*, **2014**, 52, 618-24	2.9	37
102	Harmonization of measurement results of the alcohol biomarker carbohydrate-deficient transferrin by use of the toolbox of technical procedures of the International Consortium for Harmonization of Clinical Laboratory Results. *Clinical Chemistry*, **2014**, 60, 945-53	5.5	27
101	Asymptomatic phosphomannose isomerase deficiency (MPI-CDG) initially mistaken for excessive alcohol consumption. *Clinica Chimica Acta*, **2014**, 431, 15-8	6.2	25
100	Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2013**, 73, 400-6	2	67
99	Immunoassay for ethyl glucuronide in vitreous humor: a new tool for postmortem diagnostics of alcohol use. *Forensic Science International*, **2013**, 226, 261-5	2.6	13
98	Dolichol kinase deficiency (DOLK-CDG) with a purely neurological presentation caused by a novel mutation. *Molecular Genetics and Metabolism*, **2013**, 110, 342-4	3.7	20
97	Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: III. Performance of native serum and serum spiked with disialotransferrin proves that harmonization of CDT assays is possible. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 991-6	5.9	19
96	Effect of transferrin glycation on the use of carbohydrate-deficient transferrin as an alcohol biomarker. *Alcohol and Alcoholism*, **2013**, 48, 478-82	3.5	7
95	Comparative performance of biomarkers of alcohol consumption in a population sample of working-aged men in Russia: the Izhevsk Family Study. *Addiction*, **2013**, 108, 1579-89	4.6	13
94	Alcohol and premature death in Estonian men: a study of forensic autopsies using novel biomarkers and proxy informants. *BMC Public Health*, **2012**, 12, 146	4.1	8

93	Alcohol consumption among pregnant women in a Swedish sample and its effects on the newborn outcomes. *Alcoholism: Clinical and Experimental Research*, **2012**, 36, 1779-86	3.7	39
92	The biometric measurement of alcohol consumption. *Alcoholism: Clinical and Experimental Research* , **2012**, 36, 332-41	3.7	8
91	Low plasma antibodies specific for phosphatidylethanol in alcohol abusers and patients with alcoholic pancreatitis. *Addiction Biology*, **2012**, 17, 1057-67	4.6	12
90	Monitoring of the alcohol biomarkers PEth, CDT and EtG/EtS in an outpatient treatment setting. *Alcohol and Alcoholism*, **2012**, 47, 552-7	3.5	78
89	Changes in transferrin glycosylation during pregnancy may lead to false-positive carbohydrate-deficient transferrin (CDT) results in testing for riskful alcohol consumption. *Clinica Chimica Acta*, **2011**, 412, 129-33	6.2	48
88	Method development for routine liquid chromatography-mass spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in blood. *Clinica Chimica Acta*, **2011**, 412, 1428-35	6.2	69
87	Urinary ethyl glucuronide and ethyl sulfate testing for detection of recent drinking in an outpatient treatment program for alcohol and drug dependence. *Alcohol and Alcoholism*, **2011**, 46, 278-82	3.5	33
86	Urinary ethyl glucuronide and ethyl sulfate testing for recent drinking in alcohol-dependent outpatients treated with acamprosate or placebo. *Alcohol and Alcoholism*, **2011**, 46, 553-7	3.5	29
85	Screening and brief intervention for risky alcohol consumption in the workplace: results of a 1-year randomized controlled study. *Alcohol and Alcoholism*, **2010**, 45, 252-7	3.5	47
84	Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: II. Performance of a laboratory network running the HPLC candidate reference measurement procedure and evaluation of a candidate reference material. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1585-92	5.9	34
83	Importance of HPLC confirmation of problematic carbohydrate-deficient transferrin (CDT) results from a multicapillary electrophoresis routine method. *Clinica Chimica Acta*, **2010**, 411, 1945-50	6.2	24
82	Comparison of analytical approaches for liquid chromatography/mass spectrometry determination of the alcohol biomarker ethyl glucuronide in urine. *Rapid Communications in Mass Spectrometry*, **2010**, 24, 1737-43	2.2	27
81	Molecular species of the alcohol biomarker phosphatidylethanol in human blood measured by LC-MS. *Clinical Chemistry*, **2009**, 55, 1395-405	5.5	111
80	A multi-component LC-MS/MS method for detection of ten plant-derived psychoactive substances in urine. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2009**, 877, 1162-8	3.2	53
79	Unreliable alcohol testing in a shipping safety programme. *Forensic Science International*, **2009**, 189, e45-7	2.6	20
78	Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials. *Clinical Toxicology*, **2009**, 47, 566-72	2.9	32
77	Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. *Alcohol and Alcoholism*, **2009**, 44, 55-61	3.5	142
76	Influence of alcohol use, ethnicity, age, gender, BMI and smoking on the serum transferrin glycoform pattern: implications for use of carbohydrate-deficient transferrin (CDT) as alcohol biomarker. *Clinica Chimica Acta*, **2008**, 388, 59-67	6.2	61

75	HPLC evaluation of clinical and pharmacological factors reported to cause false-positive carbohydrate-deficient transferrin (CDT) levels. *Clinica Chimica Acta*, **2008**, 389, 164-6	6.2	32
74	HPLC and mass spectrometric characterization of a candidate reference material for the alcohol biomarker carbohydrate-deficient transferrin (CDT). *Clinica Chimica Acta*, **2008**, 395, 142-5	6.2	24
73	Standardization of carbohydrate-deficient transferrin: reply to the letter by Tagliaro and Bortolotti. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46,	5.9	3
72	Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5-HIAA in a controlled drinking experiment. *Alcohol and Alcoholism*, **2008**, 43, 187-91	3.5	92
71	Insufficient standardization of a direct carbohydrate-deficient transferrin immunoassay. *Clinical Chemistry*, **2008**, 54, 1090-2	5.5	11
70	Value of ethyl glucuronide in plasma as a biomarker for recent alcohol consumption in the emergency room. *Alcohol and Alcoholism*, **2008**, 43, 431-5	3.5	40
69	Clinical characteristics of carbohydrate-deficient transferrin (%disialotransferrin) measured by HPLC: sensitivity, specificity, gender effects, and relationship with other alcohol biomarkers. *Alcohol and Alcoholism*, **2008**, 43, 436-41	3.5	45
68	Solid-phase extraction procedure for ethyl glucuronide in urine. *Journal of Analytical Toxicology*, **2008**, 32, 778-81	2.9	9
67	Comparison of ethyl glucuronide in hair with phosphatidylethanol in whole blood as post-mortem markers of alcohol abuse. *Forensic Science International*, **2008**, 176, 76-81	2.6	66
66	Evaluation of a new immunoassay for urinary ethyl glucuronide testing. *Alcohol and Alcoholism*, **2008**, 43, 46-8	3.5	81
65	Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. *Liver Transplantation*, **2007**, 13, 757-61	4.5	62
64	A pharmacokinetic study of ethyl glucuronide in blood and urine: applications to forensic toxicology. *Forensic Science International*, **2007**, 172, 119-24	2.6	121
63	Development and multicenter evaluation of the N latex CDT direct immunonephelometric assay for serum carbohydrate-deficient transferrin. *Clinical Chemistry*, **2007**, 53, 1115-21	5.5	66
62	Biomarkers to disclose recent intake of alcohol: potential of 5-hydroxytryptophol glucuronide testing using new direct UPLC-tandem MS and ELISA methods. *Alcohol and Alcoholism*, **2007**, 42, 321-5	3.5	15
61	Postcollection synthesis of ethyl glucuronide by bacteria in urine may cause false identification of alcohol consumption. *Clinical Chemistry*, **2007**, 53, 1855-7	5.5	118
60	Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45, 558-62	5.9	95
59	Determination of carbohydrate-deficient transferrin in human serum using the Bio-Rad %CDT by HPLC test. *Clinica Chimica Acta*, **2006**, 371, 187-90	6.2	38
58	Urinary tract infection: a risk factor for false-negative urinary ethyl glucuronide but not ethyl sulfate in the detection of recent alcohol consumption. *Clinical Chemistry*, **2005**, 51, 1728-30	5.5	114

57	Bench to Bedside: Mechanisms and Consequences of Alcohol-Altered Host Defenses. *Alcoholism: Clinical and Experimental Research*, **2005**, 29, 1090-1097	3.7	3
56	Comparison of HPLC and capillary electrophoresis for confirmatory testing of the alcohol misuse marker carbohydrate-deficient transferrin. *Clinical Chemistry*, **2005**, 51, 1528-31	5.5	37
55	Ethyl sulfate: a metabolite of ethanol in humans and a potential biomarker of acute alcohol intake. *Journal of Analytical Toxicology*, **2005**, 29, 270-4	2.9	108
54	Mass spectrometric identification of ethyl sulfate as an ethanol metabolite in humans. *Clinical Chemistry*, **2004**, 50, 936-7	5.5	89
53	Testing for congenital disorders of glycosylation by HPLC measurement of serum transferrin glycoforms. *Clinical Chemistry*, **2004**, 50, 954-8	5.5	51
52	Improved HPLC method for carbohydrate-deficient transferrin in serum. *Clinical Chemistry*, **2003**, 49, 1881-90	5.5	142
51	Urinary ethyl glucuronide and 5-hydroxytryptophol levels during repeated ethanol ingestion in healthy human subjects. *Alcohol and Alcoholism*, **2003**, 38, 347-51	3.5	30
50	Ethyl glucuronide concentrations in two successive urinary voids from drinking drivers: relationship to creatinine content and blood and urine ethanol concentrations. *Forensic Science International*, **2003**, 133, 86-94	2.6	51
49	5-hydroxytryptophol as a marker for recent alcohol intake. *Addiction*, **2003**, 98 Suppl 2, 63-72	4.6	36
48	Biological markers in alcoholism. *Journal of Neural Transmission Supplementum*, **2003**, 15-32		28
47	The Alcohol Use Disorders Identification Test and Carbohydrate-Deficient Transferrin in Alcohol-Related Sickness Absence. *Alcoholism: Clinical and Experimental Research*, **2002**, 26, 28-35	3.7	14
46	CDT, GGT, and AST As Markers of Alcohol Use: The WHO/ISBRA Collaborative Project. *Alcoholism: Clinical and Experimental Research*, **2002**, 26, 332-339	3.7	205
45	Laboratory Tests for Acute Alcohol Consumption: Results of the WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence. *Alcoholism: Clinical and Experimental Research*, **2002**, 26, 1070-1077	3.7	48
44	The Effect of Total Body Water on the Relationship Between Alcohol Consumption and Carbohydrate-Deficient Transferrin. *Alcoholism: Clinical and Experimental Research*, **2002**, 26, 1097-1104	3.7	8
43	Comparison of urinary excretion characteristics of ethanol and ethyl glucuronide. *Journal of Analytical Toxicology*, **2002**, 26, 201-4	2.9	170
42	Multicentre validation study of instrument applications for %CDT, an immunoassay for quantification of carbohydrate-deficient transferrin in serum. *Alcohol and Alcoholism*, **2002**, 37, 209-12	3.5	9
41	Direct quantification of ethyl glucuronide in clinical urine samples by liquid chromatography-mass spectrometry. *Therapeutic Drug Monitoring*, **2002**, 24, 645-51	3.2	103
40	Laboratory tests for acute alcohol consumption: results of the WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence. *Alcoholism: Clinical and Experimental Research*, **2002**, 26, 1070-7	3.7	15

39	Perioperative morbidity and mortality in chronic alcoholic patients. *Alcoholism: Clinical and Experimental Research*, **2001**, 25, 164S-170S	3.7	24
38	WHO/ISBRA Study on State and Trait Markers in Alcoholism. *Alcoholism: Clinical and Experimental Research*, **2001**, 25, 99S-103S	3.7	6
37	Perioperative Morbidity and Mortality in Chronic Alcoholic Patients. *Alcoholism: Clinical and Experimental Research*, **2001**, 25, 164S-170S	3.7	86
36	Comparison of self-reported alcohol intake with the urinary excretion of 5-hydroxytryptophol:5-hydroxyindole-3-acetic acid, a biomarker of recent alcohol intake. *British Journal of Nutrition*, **2001**, 85, 621-7	3.6	21
35	Study of Axis-Shield new %CDT immunoassay for quantification of carbohydrate-deficient transferrin (CDT) in serum. *Alcohol and Alcoholism*, **2001**, 36, 406-12	3.5	61
34	Interference of Transferrin Isoform Types with Carbohydrate-deficient Transferrin Quantification in the Identification of Alcohol Abuse. *Clinical Chemistry*, **2001**, 47, 1225-1233	5.5	148
33	WHP/ISBRA study on state and trait markers in alcoholism. *Alcoholism: Clinical and Experimental Research*, **2001**, 25, 99S-103S	3.7	1
32	Biological Markers of Alcohol Use and Abuse in Theory and Practice **2001**, 177-205		7
31	Interference of transferrin isoform types with carbohydrate-deficient transferrin quantification in the identification of alcohol abuse. *Clinical Chemistry*, **2001**, 47, 1225-33	5.5	23
30	Platelet Adenylyl Cyclase Activity as a Trait Marker of Alcohol Dependence. *Alcoholism: Clinical and Experimental Research*, **2000**, 24, 810-821	3.7	22
29	The Alcohol Use Disorders Identification Test (AUDIT) and Carbohydrate-Deficient Transferrin (CDT) in a Routine Workplace Health Examination. *Alcoholism: Clinical and Experimental Research*, **2000**, 24, 180-187	3.7	52
28	The Alcohol Use Disorders Identification Test (AUDIT) and Carbohydrate-Deficient Transferrin (CDT) in a Routine Workplace Health Examination **2000**, 24, 180		5
27	Platelet Adenylyl Cyclase Activity as a Trait Marker of Alcohol Dependence **2000**, 24, 810		6
26	Absolute or Relative Measurement of Carbohydrate-deficient Transferrin in Serum? Experiences with Three Immunological Assays. *Clinical Chemistry*, **1999**, 45, 131-135	5.5	50
25	Activities of human alcohol dehydrogenases in the metabolic pathways of ethanol and serotonin. *FEBS Journal*, **1999**, 262, 324-9		47
24	Comparison of urinary 5-hydroxytryptophol, breath ethanol, and self-report for detection of recent alcohol use during outpatient treatment: a study on methadone patients. *Drug and Alcohol Dependence*, **1999**, 56, 33-8	4.9	41
23	Time Course and Reproducibility of Urinary Excretion Profiles of Ethanol, Methanol, and the Ratio of Serotonin Metabolites After Intravenous Infusion of Ethanol. *Alcoholism: Clinical and Experimental Research*, **1999**, 23, 1921-1926	3.7	13
22	Absolute or relative measurement of carbohydrate-deficient transferrin in serum? Experiences with three immunological assays. *Clinical Chemistry*, **1999**, 45, 131-5	5.5	4

21	Monitoring Relapse Drinking During Disulfiram Therapy by Assay of Urinary 5-Hydroxytryptophol. *Alcoholism: Clinical and Experimental Research*, **1998**, 22, 111-114	3.7	29
20	Intra- and interindividual variability of carbohydrate-deficient transferrin, □glutamyltransferase, and mean corpuscular volume in teetotalers. *Clinical Chemistry*, **1998**, 44, 2120-2125	5.5	37
19	Monitoring relapse drinking during disulfiram therapy by assay of urinary 5-hydroxytryptophol. *Alcoholism: Clinical and Experimental Research*, **1998**, 22, 111-4	3.7	2
18	Intra- and interindividual variability of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume in teetotalers. *Clinical Chemistry*, **1998**, 44, 2120-5	5.5	4
17	Biochemical markers of alcohol use and abuse: experiences from the Pilot Study of the WHO/ISBRA Collaborative Project on state and trait markers of alcohol. International Society for Biomedical Research on Alcoholism. *Alcohol and Alcoholism*, **1997**, 32, 133-44	3.5	47
16	Elevated brain 5-hydroxytryptophol levels in experimental portal-systemic encephalopathy. *Basic and Clinical Pharmacology and Toxicology*, **1997**, 80, 187-90		5
15	Laboratory testing for recent alcohol consumption: comparison of ethanol, methanol, and 5-hydroxytryptophol. *Clinical Chemistry*, **1996**, 42, 618-624	5.5	72
14	Longitudinal comparison of carbohydrate-deficient transferrin and gamma-glutamyl transferase: complementary markers of excessive alcohol consumption. *Alcohol and Alcoholism*, **1996**, 31, 101-7	3.5	73
13	Carbohydrate-deficient transferrin and gamma-glutamyl transferase levels during disulfiram therapy. *Alcoholism: Clinical and Experimental Research*, **1996**, 20, 1202-5	3.7	36
12	Laboratory testing for recent alcohol consumption: comparison of ethanol, methanol, and 5-hydroxytryptophol. *Clinical Chemistry*, **1996**, 42, 618-24	5.5	7
11	5-Hydroxytryptophol conjugation in man: influence of alcohol consumption and altered serotonin turnover. *Life Sciences*, **1995**, 56, 1529-34	6.8	17
10	Changes in serotonin metabolism during treatment with the aldehyde dehydrogenase inhibitors disulfiram and cyanamide. *Basic and Clinical Pharmacology and Toxicology*, **1995**, 77, 323-6		24
9	Detection of relapses in alcohol-dependent patients using carbohydrate-deficient transferrin: improvement with individualized reference levels during long-term monitoring. *Alcoholism: Clinical and Experimental Research*, **1995**, 19, 961-3	3.7	51
8	Distinguishing ingested ethanol from microbial formation by analysis of urinary 5-hydroxytryptophol and 5-hydroxyindoleacetic acid. *Journal of Forensic Sciences*, **1995**, 40, 95-8	1.8	1
7	Distinguishing Ingested Ethanol from Microbial Formation by Analysis of Urinary 5-Hydroxytryptophol and 5-Hydroxyindoleacetic Acid. *Journal of Forensic Sciences*, **1995**, 40, 13768J	1.8	32
6	The use of 5-hydroxytryptophol as an alcohol intake marker. *Alcohol and Alcoholism Supplement*, **1994**, 2, 497-502		7
5	Distribution of acetaldehyde in human blood: effects of ethanol and treatment with disulfiram. *Alcohol and Alcoholism*, **1993**, 28, 461-8	3.5	12
4	Aldehyde dehydrogenase in blood: distribution, characteristics and possible use as marker of alcohol misuse. *Alcohol and Alcoholism*, **1993**, 28, 135-45	3.5	10

3	Comparison of blood aldehyde dehydrogenase activities in moist snuff users, cigarette smokers and nontobacco users. *Alcoholism: Clinical and Experimental Research*, **1991**, 15, 1-6	3.7	15
2	Use of leukocyte aldehyde dehydrogenase activity to monitor inhibitory effect of disulfiram treatment. *Alcoholism: Clinical and Experimental Research*, **1990**, 14, 48-52	3.7	10
1	Chromatographic Measurement of Transferrin Glycoforms for Detecting Alcohol Abuse and Congenital Disorders of Glycosylation87-100		2